Investing Across the Spectrum of Health Care

Working Towards Better, Faster & Less Expensive Health Care.

Great Point Partners brings its sector expertise to two separate but complementary strategies – lower middle market growth buyout funds investing in private health care companies and a hedge fund investing in public life sciences companies.

Great Point Partners was founded in 2003 with a vision of helping growing health care companies achieve their full potential while improving global health care.

By the Numbers

$1.7 B

In Private and Public Equity AUM


years of industry experience


industry professionals

CEO & Medical

advisory boards

Learn More About Us
Hear from our Private Equity CEOs
Rob Gelb

On Investing for Business Expansion
Ray Hill

On Investing to Accelerate Growth
Scott Houlton

On Growing Revenue 72% p.a.
Darren Head

On Growing Revenue 45% p.a.
Martin LeBlanc

On Partnering with GPP
Russel Sherlock

On 11 Tuck-ins

Funding Transformational Health Care Companies

Great Point Partners Private Equity seeks to invest in growing, profitable health care companies that are led by management teams focused on achieving accelerated and sustainable growth.

Great Point Partners serves as an experienced investor and partner to management teams who share our objectives. Companies choose to work with Great Point Partners because of our health care expertise, our industry contacts and our focus on helping strong management teams grow their businesses.

Private Equity Partnership Philosophy

Supporting Innovation in Drug Development

The BioMedical Value Fund (“BMVF”) seeks to invest in small and mid-capitalization, publicly traded biotechnology and life sciences companies with great technology that will dramatically improve how diseases are treated and managed.

The BMVF team of MDs, PhDs and PharmDs employs a deep value, fundamentally focused investment approach, leveraging a proprietary research team with deep financial and scientific expertise and strives to identify asymmetric risk reward dynamics within the universe of publicly traded life sciences companies.

Public Equity